CIDGMed:基于因果推断驱动的增强双粒度学习药物推荐方法
CIDGMed: Causal Inference-Driven Medication Recommendation with Enhanced Dual-Granularity Learning
AI总结:
针对现有药物推荐方法存在因果关系挖掘不足、多粒度信息整合缺失导致的偏差问题,提出融合因果推断与双粒度药物表示学习的CIDGMed方法,搭配偏差校正模型,在准确率、安全性与效率上均优于现有最优模型。
摘要:
药物推荐旨在整合患者的长期健康记录,为特定健康状态提供准确且安全的药物组合方案。现有方法往往未能深入挖掘疾病/手术操作与药物之间的真实因果关系,导致推荐结果存在偏差。此外,在药物表示学习中,粗粒度(药物本身)与细粒度(分子层面)等不同粒度的药物信息之间的关联未得到有效整合,进而造成表示学习存在偏差。为解决上述局限,我们提出了因果推断驱动的双粒度药物推荐方法CIDGMed。该方法利用因果推断揭示疾病/手术操作与药物之间的关联,从而提升推荐的合理性与可解释性。通过将粗粒度药物效用与细粒度分子结构信息相融合,CIDGMed能够生成药物的全面表示。此外,我们在预测阶段采用偏差校正模型进一步优化推荐结果,兼顾准确性与安全性。大量实验表明,CIDGMed在多项指标上显著优于当前最先进模型,其中准确率提升2.54%,副作用发生率降低3.65%,时间效率提升39.42%。我们还通过案例分析验证了CIDGMed的合理性。
英文摘要:
Medication recommendation aims to integrate patients' long-term health records to provide accurate and safe medication combinations for specific health states. Existing methods often fail to deeply explore the true causal relationships between diseases/procedures and medications, resulting in biased recommendations. Additionally, in medication representation learning, the relationships between information at different granularities of medications, coarse-grained (medication itself) and fine-grained (molecular level), are not effectively integrated, leading to biases in representation learning. To address these limitations, we propose the Causal Inference-driven Dual-Granularity Medication Recommendation method (CIDGMed). Our approach leverages causal inference to uncover the relationships between diseases/procedures and medications, thereby enhancing the rationality and interpretability of recommendations. By integrating coarse-grained medication effects with fine-grained molecular structure information, CIDGMed provides a comprehensive representation of medications. Additionally, we employ a bias correction model during the prediction phase to further refine recommendations, ensuring both accuracy and safety. Through extensive experiments, CIDGMed significantly outperforms current state-of-the-art models across multiple metrics, achieving a 2.54% increase in accuracy, a 3.65% reduction in side effects, and a 39.42% improvement in time efficiency. Additionally, we demonstrate the rationale of CIDGMed through a case study.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。